Although we’ve accomplished a great deal over the years, the fact remains that while colorectal cancer (CRC) is preventable, it continues to be a leading cause of cancer death in Canada. Moreover, we are faced with new challenges, such as rising rates of CRC in young adults and keeping up to date on advancements in research and development.
Our various initiatives allow CCC to continue to advocate for the well-being of CRC patients and those at risk.
The Foods That Fight Cancer (FTFC) program educates Canadians about incorporating healthy, nutritional and fun choices into their daily diets, providing them with recipes that will assist them in making the right food choices in helping them to prevent colorectal cancer and other cancers as well. The anti-cancer properties contained in the recipes have the additional benefit of increasing the chances of surviving cancer in the long run.
The Patient Values Project (PVP) aims to define patient values, and measure and assign a weight to patient values in cancer drug treatment to ensure Canadian patients are heard in the evaluation of cancer care and the reimbursement of cancer drugs by public agencies. These weights will be adopted by Canadian and international cancer patient groups to empower them to provide objective input regarding patient values and preferences to inform the Health Technology Assessment (HTA) deliberative process. The PVP will increase timely access to effective treatments, and allow for a more reasoned and balanced rationale in the assessment of new cancer drugs by the expert committees.
The Patient Group Pathway Model to Accessing Cancer Clinical Trials is a Colorectal Cancer Canada (CCC) initiative which aims to increase recruitment, participation and retention rates of cancer clinical trials within Canada. A consensus meeting and a working group meeting were hosted by CCC in 2017 and recommendations on increasing uptake were published in Current Oncology in 2018. In 2018, a conference regarding The Patient Group Pathway Model and Real World Evidence Conference was hosted to draft a Patient Charter for clinical trial stakeholders. In 2019, a two-day conference was organized to foster patient group partnerships among stakeholders who advocate for cancer clinical trials in Canada and the development of Real World Evidence to help reduce uncertainty in clinical trial results.READ OUR PUBLICATION
Real World Evidence (RWE) is the third component to our patient-centric national “Trilogy” initiative. It focuses on the ability to collect data from clinical trials so that the best treatment paths can be uncovered for patients in clinical practice. CCC will be working to continue to capture the patient perspective across the continuum of colorectal cancer care.
The Get Personal Campaign aims to raise awareness and advocate for timely reflex biomarker testing to ensure the most appropriate personalized treatment plan is developed according to the genetic makeup of a patient's tumor and personal set of disease characteristics. The use of biomarkers helps to create a more personalized approach to cancer care that will allow patients to make more informed decisions on the type of treatment given. The campaign specifically aims to provide information through educational materials on the comprehensive array of treatment options and health services for metastatic colorectal cancer (mCRC) patients in Canada. It also aims to raise awareness among patients, clinicians and policy-makers of the full range of biomarker tests and mCRC treatments. Through the Get Personal campaign, we aim to highlight variations in mCRC treatments across Canada and assess needs and gaps in Canadian mCRC care through patient experiences.
The Never Too Young (N2Y) Program brings much-needed awareness and education to the forefront when it comes to early age onset colorectal cancer. Colorectal cancer has risen at an alarming rate in young people and we are committed to learning more and providing support for those currently in their fight as the needs, interests and concerns among this population vary greatly compared to their older counterparts. This is vital as incidence among Canadians under 50 is rising significantly. Individuals born after 1990 have twice the risk of colon cancer and four times the risk of rectal cancer compared to people born around 1950. N2Y also aims to raise awareness among the general population to increase early detection and improve outcomes for early age onset patients.